journal article
Open Access
Dec 16, 2022
Landscape of TB Infection and Prevention among People Living with HIV
Abstract
Tuberculosis (TB) is one of the leading causes of mortality in people living with HIV (PLHIV) and contributes to up to a third of deaths in this population. The World Health Organization guidelines aim to target early detection and treatment of TB among PLHIV, particularly in high-prevalence and low-resource settings. Prevention plays a key role in the fight against TB among PLHIV. This review explores TB screening tools available for PLHIV, including symptom-based screening, chest radiography, tuberculin skin tests, interferon gamma release assays, and serum biomarkers. We then review TB Preventive Treatment (TPT), shown to reduce the progression to active TB and mortality among PLHIV, and available TPT regimens. Last, we highlight policy-practice gaps and barriers to implementation as well as ongoing research needs to lower the burden of TB and HIV coinfection through preventive activities, innovative diagnostic tests, and cost-effectiveness studies.
Topics
No keywords indexed for this article. Browse by subject →
References
83
[1]
WHO (2021). WHO Global Tuberculosis Report 2021.
[2]
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Rein M. G. J. Houben, Peter J. Dodd
PLoS Medicine
10.1371/journal.pmed.1002152
[3]
Ford "TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: A systematic review and meta-analysis" J. Int. AIDS Soc. (2016) 10.7448/ias.19.1.20714
[4]
UNAIDS (2022, August 24). Tuberculosis and AIDS. Available online: https://www.unaids.org/sites/default/files/media_asset/20220324_TB_FactSheet_en.pdf.
[5]
Mollel "Effect of tuberculosis infection on mortality of HIV-infected patients in Northern Tanzania" Trop. Med. Health (2020) 10.1186/s41182-020-00212-z
[6]
World Health Organization (2021). WHO Guidelines on Screening for Tuberculosis.
[7]
WHO (2022). WHO Operational Handbook on Tuberculosis. Module 5: Management of Tuberculosis in Children and Adolescents.
[8]
World Health Organization (2021). WHO Consolidated Guidelines on Tuberculosis. Module 1: Prevention. Tuberculosis Preventive Treatment. Tuberculosis, Lung Diseases, HIV Infection.
10.30978/tb2021-2-86
[9]
Getahun, H., Kittikraisak, W., Heilig, C.M., Corbett, E.L., Ayles, H., Cain, K.P., Grant, A.D., Churchyard, G.J., Kimerling, M., and Shah, S. (2011). Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-Analysis of Observational Studies. PLoS Med., 8.
10.1371/journal.pmed.1000391
[10]
World Health Organization (2018). Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management.
[11]
Vonasek "Screening tests for active pulmonary tuberculosis in children. Cochrane Infectious Diseases Group, editor" Cochrane Database Syst. Rev. (2021)
[12]
World Health Organization (2022, September 18). Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings, Available online: https://apps.who.int/iris/handle/10665/44472HO.
[13]
Sawry "Evaluation of the intensified tuberculosis case finding guidelines for children living with HIV" Int. J. Tuberc. Lung Dis. (2018) 10.5588/ijtld.17.0825
[14]
Vonasek "Tuberculosis symptom screening for children and adolescents living with HIV in six high HIV/TB burden countries in Africa" AIDS (2021) 10.1097/qad.0000000000002715
[15]
Verkuijl "Performance of symptom-based tuberculosis screening among people living with HIV: Not as great as hoped" AIDS (2014) 10.1097/qad.0000000000000278
[16]
Hanifa "Tuberculosis among adults starting antiretroviral therapy in South Africa: The need for routine case finding" Int. J. Tuberc. Lung Dis. (2012) 10.5588/ijtld.11.0733
[17]
Kerkhoff, A.D., Wood, R., Lowe, D.M., Vogt, M., and Lawn, S.D. (2013). Blood neutrophil counts in HIV-infected patients with pulmonary tuberculosis: Association with sputum mycobacterial load. PLoS ONE, 8.
10.1371/journal.pone.0067956
[18]
Kufa "Undiagnosed tuberculosis among HIV clinic attendees: Association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control" J. Acquir. Immune Defic. Syndr. (2012) 10.1097/qai.0b013e318251ae0b
[19]
Modi, S., Cavanaugh, J.S., Shiraishi, R.W., Alexander, H.L., McCarthy, K.D., Burmen, B., Muttai, H., Heilig, C.M., Nakashima, A.K., and Cain, K.P. (2016). Performance of Clinical Screening Algorithms for Tuberculosis Intensified Case Finding among People Living with HIV in Western Kenya. PLoS ONE, 11.
10.1371/journal.pone.0167685
[20]
Swindells "Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253" Int. J. Tuberc. Lung Dis. (2013) 10.5588/ijtld.12.0737
[21]
Thit, S.S., Aung, N.M., Htet, Z.W., Boyd, M.A., Saw, H.A., Anstey, N.M., Kyi, T.T., Cooper, D.A., Kyi, M.M., and Hanson, J. (2017). The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: An observational study. BMC Med., 15.
10.1186/s12916-017-0888-3
[22]
Affolabi, D., Wachinou, A.P., Bekou, W., Zannou, D.M., Cisse, M., and Ngom Gueye, N.F. (2018, January 24–27). Screening tuberculosis in HIV infected patients: Which algorithms work best? A multicountry survey in Benin, Guinea and Senegal (RAFAscreen project). Proceedings of the 49th Union World Conference on Lung Health, The Hague, The Netherlands.
[23]
World Health Organization (2021). WHO Consolidated Guidelines on Tuberculosis: Module 2: Screening: Systematic Screening for Tuberculosis Disease. Web Annex C: GRADE Evidence to Decision Tables.
[24]
Vasiliu "Symptom-Based Screening Versus Chest Radiography for TB Child Contacts: A Systematic Review and Meta-Analysis" Pediatr. Infect. Dis. J. (2021) 10.1097/inf.0000000000003265
[25]
Yoon "Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: A diagnostic accuracy study" Lancet Infect. Dis. (2017) 10.1016/s1473-3099(17)30488-7
[26]
Shapiro "C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa" AIDS (2018) 10.1097/qad.0000000000001902
[27]
Markowitz "Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group" Ann. Intern. Med. (1993) 10.7326/0003-4819-119-3-199308010-00002
[28]
Santin, M., Muñoz, L., and Rigau, D. (2012). Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: A systematic review and meta-analysis. PLoS ONE, 7.
10.1371/journal.pone.0032482
[29]
Aichelburg "Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals" Clin. Infect. Dis. (2009) 10.1086/597351
[30]
Luetkemeyer "Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals" Am. J. Respir. Crit. Care Med. (2007) 10.1164/rccm.200608-1088oc
[31]
Cattamanchi "Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: A systematic review and meta-analysis" J. Acquir. Immune Defic. Syndr. (2011) 10.1097/qai.0b013e31820b07ab
[32]
Rangaka "Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection" Am. J. Respir. Crit. Care Med. (2007) 10.1164/rccm.200610-1439oc
[33]
Dheda "T-cell interferon-γ release assays for the rapid immunodiagnosis of tuberculosis: Clinical utility in high-burden vs. low-burden settings" Curr. Opin. Pulm. Med. (2009) 10.1097/mcp.0b013e32832a0adc
[34]
NIH (2022, August 18). Mycobacterium tuberculosis Infection and Disease, Available online: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/mycobacterium-0.
[35]
Elzi "Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission" Clin. Infect. Dis. (2007) 10.1086/510080
[36]
Matoga "Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy" Clin. Infect. Dis. (2021) 10.1093/cid/ciab179
[37]
Akolo "Treatment of latent tuberculosis infection in HIV infected persons" Cochrane Database Syst. Rev. (2010)
[38]
Badje "Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: Long-term follow-up of the Temprano ANRS 12136 trial" Lancet Glob. Health (2017) 10.1016/s2214-109x(17)30372-8
[39]
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
New England Journal of Medicine
10.1056/nejmoa1507198
[40]
World Health Organization (2020). WHO Consolidated Guidelines on Tuberculosis. Module 1: Prevention—Tuberculosis Preventive Treatment.
10.30978/tb2021-2-86
[41]
Sterling "Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020" Morbid. Mortal. Wkly. Rep. (2020)
[42]
Hawken "Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: Results of a randomized controlled trial" AIDS (1997) 10.1097/00002030-199707000-00006
[43]
Whalen "A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration" N. Engl. J. Med. (1997) 10.1056/nejm199709183371201
[44]
Gordin "Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized Trial" JAMA (2000) 10.1001/jama.283.11.1445
[45]
Fitzgerald "No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: Results of a randomized trial" J. Acquir. Immune Defic. Syndr. (2001) 10.1097/00042560-200111010-00018
[46]
Zar "Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: Randomised controlled trial" BMJ (2007) 10.1136/bmj.39000.486400.55
[47]
Madhi "Primary Isoniazid Prophylaxis against Tuberculosis in HIV-Exposed Children" N. Engl. J. Med. (2011) 10.1056/nejmoa1011214
[48]
Martinson "New Regimens to Prevent Tuberculosis in Adults with HIV Infection" N. Engl. J. Med. (2011) 10.1056/nejmoa1005136
[49]
Samandari "6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: A randomised, double-blind, placebo-controlled trial" Lancet (2011) 10.1016/s0140-6736(11)60204-3
[50]
Rangaka "Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial" Lancet (2014) 10.1016/s0140-6736(14)60162-8
Showing 50 of 83 references
Metrics
8
Citations
83
References
Details
- Published
- Dec 16, 2022
- Vol/Issue
- 11(12)
- Pages
- 1552
- License
- View
Authors
Cite This Article
Anca Vasiliu, Rebecca Abelman, Yousra Kherabi, et al. (2022). Landscape of TB Infection and Prevention among People Living with HIV. Pathogens, 11(12), 1552. https://doi.org/10.3390/pathogens11121552
Related
You May Also Like
Bacterial Antibiotic Resistance: The Most Critical Pathogens
Giuseppe Mancuso, Angelina Midiri · 2021
1,144 citations
Acinetobacter baumannii Antibiotic Resistance Mechanisms
Ioannis Kyriakidis, Eleni Vasileiou · 2021
528 citations
From in vitro to in vivo Models of Bacterial Biofilm-Related Infections
David Lebeaux, Ashwini Chauhan · 2013
456 citations
Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks
Hossam M. Ashour, Walid F. Elkhatib · 2020
427 citations
Phenylpropanoid Pathway Engineering: An Emerging Approach towards Plant Defense
Vivek Yadav, Zhongyuan Wang · 2020
423 citations